DUBLIN – Pharmaleads SAS is like the comeback kid who never went away. The French drug developer has spent a decade quietly focused on a novel drug mechanism in pain that was long disregarded by others in the field. The accrual of preclinical and early clinical data on its two lead drug candidates, combined with findings from other labs, have now brought it to the point where the rubber hits the road.
DUBLIN – Apeiron Biologics AG gained formal European Commission approval last week for dinutuximab beta as a treatment for pediatric neuroblastoma, a historic milestone for the Austrian biotech company and one that puts it on a firm financial footing.
DUBLIN – Shares in Poxel SA opened Thursday at €10.22 (US$11.21) on the Euronext exchange in Paris, up 56 percent on the previous close, in response to positive top-line data from a phase IIb trial in Japan of imeglimin in 299 patients with type 2 diabetes.
DUBLIN – Sosei Group is paying £35 million (US$45.2 million) for a 25.6 percent stake in Mina Therapeutics Ltd. in a deal that gives it a commanding view of the emerging field of small activating RNA (saRNA) therapeutics.
DUBLIN – Inflaming the tumor microenvironment has become the focus of a wide-ranging effort on the part of immuno-oncology researchers vying to boost the response rates of cancer immunotherapies. The approaches vary widely, from combinations of immune checkpoint inhibitors to single checkpoint inhibitors combined with any number of agents, including traditional chemotherapy, radiotherapy, oncolytic viruses, targeted cancer drugs, cancer vaccines and other immunostimulatory treatments. The overriding aim is to turn off tumor-mediated immune suppression and to promote T-cell infiltration of tumors and recognition of cancer cells.
DUBLIN – Shares in Poxel SA opened Thursday at €10.22 (US$11.21) on the Euronext exchange in Paris, up 56 percent on the previous close, in response to positive top-line data from a phase IIb trial in Japan of imeglimin in 299 patients with type 2 diabetes.
DUBLIN – Pieris Pharmaceuticals Inc. has laid down a big marker for its credentials in respiratory disease through an alliance with Astrazeneca plc under which it is receiving $57.5 million in up-front and near-term milestone payments and up to $2.1 billion more in development milestones and commercial payments, as well as tiered royalties on product sales.
DUBLIN – Sosei Group is paying £35 million (US$45.2 million) for a 25.6 percent stake in Mina Therapeutics Ltd. in a deal that gives it a commanding view of the emerging field of small activating RNA (saRNA) therapeutics.
DUBLIN – Shares in Abivax SA surged by more than 175 percent during trading Tuesday on news that its HIV maturation inhibitor, ABX-464, may be able to reduce viral reservoirs in HIV-infected patients who already have undetectable plasma viral load.
DUBLIN – Kiadis Pharma NV filed a marketing authorization application (MAA) with the EMA for ATIR-101, an adjunctive treatment for patients with hematological malignancies undergoing haploidentical (partially matched) allogeneic hematopoietic stem cell transplantation (HSCT).
